Skip to main content

Table 3 Novel therapeutics in Polycythemia Vera

From: Erythropoiesis: insights into pathophysiology and treatments in 2017

Company Drug Mechanism Eligibility Route Clintrials.gov Status
Small molecules targets
 Incyte Coproration Novartis Jak 1/2 inhibitor (ruxolitinib) vs BAT Cytoreduction - age ≥ 18 years Oral NCT01243944 Active, not recruiting
- Phase 3
 Incyte Jak 1/2 inhibitor (ruxolitinib) vs HU Cytoreduction - age ≥ 18 years Oral NCT01632904 Completed
- Phase 3
 AOP Orphan Pharmaceuticals AG Pegylated interferon alpha-2b (AOP2014) vs HU Cytoreduction - age ≥ 18 years subcutaneously NCT01949805 Completed
- Phase 3
 Roskilde University Hospital, Vorinostat Cytoreduction - age ≥ 18 years Oral Completed
- Phase 2
 Italframaco Givinostat vs HU Cytoreduction - age ≥ 18 years Oral NCT00928707 Completed
- Phase 2
  1. BAT best available therapy
  2. HU hydroxyurea